MCLEAN, Va., June 25, 2018 /PRNewswire/ -- Food Allergy
Research & Education (FARE), the nation's leading food allergy
advocacy organization, is pleased to announce the election of
David G. Bunning to its Board of
Directors.
Bunning, whose philanthropic work over the past 15 years has
played a critical role in accelerating food allergy research
nationwide, previously served on FARE's Board and will now serve as
Chair. He is the founder, CEO and Chief Investment Officer of The
TLP Group LLC.
Bunning and his wife Denise, an educator, Board member,
co-founder of the food allergy support group MOCHA and co-author of
The Food Allergy Experience, are longtime members of the food
allergy community. Their two sons grew up with life-threatening
food allergies to milk, egg and beef, among others. One of their
sons also has eosinophilic esophagitis. The Bunnings received the
FARE Vision Award in 2015 for the exceptional actions the family
has taken to find a cure for food allergies while providing support
and resources to all those affected.
"We are thrilled to welcome Dave back to the Board of Directors.
He is a visionary who has demonstrated an extraordinary commitment
to make the world safer for individuals with food allergies. We
look forward to working with Dave as well as FARE's new CEO,
Lisa Gable, as we continue to make a
transformative impact on behalf of the 15 million Americans with
food allergies," said Janet Atwater,
a member of FARE's Board of Directors.
In 2006, Dave and Denise founded the Food Allergy Project, which
supported vital research initiatives at leading institutions and
later merged with the Food Allergy Initiative, one of FARE's
predecessor organizations. For more than a decade, the Bunnings and
their family foundation have provided funding for food allergy
research at Stanford University, Ann
& Robert H. Lurie Children's Hospital of Chicago, Duke
University, Johns Hopkins
University and other leading research institutions. The
Bunnings also have supported endowed professorships at University of Chicago, Cincinnati Children's
Hospital Medical Center, Northwestern
University Feinberg School of Medicine and Boston Children's
Hospital, the primary teaching affiliate of Harvard Medical School.
"It is a tremendous honor to return to the Board of Directors at
FARE, an advocacy organization that alone or through its
predecessor organizations has accomplished so much over the last 15
years as the incidence of food allergy has reached nearly every
classroom in America," Bunning said. "Among its many recent
achievements, FARE has established the FARE Clinical Network to
accelerate the development of treatments and improve the quality of
care, brought innovative scientists into the field and worked
tirelessly on issues of inclusion and safety for our community
through its advocacy and education programs. FARE also brought
together advocates, the research community, the FDA and the NIH at
its inaugural research retreat in 2011, which, among other things,
led to the formation of Aimmune Therapeutics, a company that
recently completed Phase 3 trials for its peanut allergy therapy. I
am very pleased to be a part of FARE's next chapter as we reimagine
what the future looks like for all of us who are affected by
life-threatening food allergies."
For more information about FARE and food allergies, visit
www.foodallergy.org.
ABOUT FARE
Food Allergy Research &
Education (FARE) works on behalf of the 15 million Americans with
food allergies, including all those at risk for life-threatening
anaphylaxis. This potentially deadly disease affects 1 in every 13
children in the U.S. – or roughly two in every classroom. FARE's
mission is to improve the quality of life and the health of
individuals with food allergies, and to provide them hope through
the promise of new treatments. For more information, please visit
www.foodallergy.org.
View original
content:http://www.prnewswire.com/news-releases/david-g-bunning-elected-as-chair-board-of-directors-at-food-allergy-research--education-300671449.html
SOURCE Food Allergy Research & Education